Cited by 1,088Cystic Fibrosis Research AdvancesIon Transport and Channel RegulationInhalation and Respiratory Drug Delivery

The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.

Correction of the F508del-CFTR protein processing defect in vitro by the investigational drug VX-809

Open access

Van Goor, Fredrick, Hadida, Sabine, Grootenhuis, Peter D. J., Burton, Bill, Stack, Jeffrey H., Straley, Kimberly S., Decker, Caroline J., Miller, Mark, McCartney, Jason, Olson, Eric R., Wine, Jeffrey J., Frizzell, Ray A., Ashlock, Melissa, Negulescu, Paul A.·2011·Proceedings of the National Academy of Sciences

DOI 10.1073/pnas.1105787108PMC PMC3219147

Open this paper in CoChat — free account

Abstract

Cystic fibrosis (CF) is caused by mutations in the CF transmembrane conductance regulator ( CFTR ) gene that impair the function of CFTR, an epithelial chloride channel required for proper function of the lung, pancreas, and other organs. Most patients with CF carry the F508del CFTR mutation, which causes defective CFTR protein folding and processing in the endoplasmic reticulum, resulting in minimal amounts of CFTR at the cell surface. One strategy to treat these patients is to correct the processing of F508del-CFTR with small molecules. Here we describe the in vitro pharmacology of VX-809, a CFTR corrector that was advanced into clinical development for the treatment of CF. In cultured human bronchial epithelial cells isolated from patients with CF homozygous for F508del, VX-809 improved F508del-CFTR processing in the endoplasmic reticulum and enhanced chloride secretion to approximately 14% of non-CF human bronchial epithelial cells (EC 50 , 81 ± 19 nM), a level associated with mild CF in patients with less disruptive CFTR mutations. F508del-CFTR corrected by VX-809 exhibited biochemical and functional characteristics similar to normal CFTR, including biochemical susceptibility to proteolysis, residence time in the plasma membrane, and single-channel open probability. VX-809 was more efficacious and selective for CFTR than previously reported CFTR correctors. VX-809 represents a class of CFTR corrector that specifically addresses the underlying processing defect in F508del-CFTR.

Integrity signals

Registry

Crossref · 10.1073/pnas.1105787108

Cites

44 of 44 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Identification of the Cystic Fibrosis Gene: Cloning and Characterization of Complementary DNA
Riordan, J. R., Rommens, J. M., Kerem, B.-S., Alon, N., Rozmahel, R., Grzelczak, Z., Zielenski, J., Lok, S., Plavsic, N., Chou, J.-L., et al. (1989) · Science · doi:10.1126/science.2475911 · Cited by 7,418
Defective intracellular transport and processing of CFTR is the molecular basis of most cystic fibrosis
Cheng, S. H., Gregory, R. J., Marshall, J., Paul, S., Souza, D. W., White, G. A., O’Riordan, C. R., & Smith, A. E. (1990) · Cell · doi:10.1016/0092-8674(90)90148-8 · Cited by 1,792
Processing of mutant cystic fibrosis transmembrane conductance regulator is temperature-sensitive
Denning, G. M., Anderson, M. P., Amara, J. F., Marshall, J., Smith, A. E., & Welsh, M. J. (1992) · Nature · doi:10.1038/358761a0 · Cited by 1,236
Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770
Goor, F. V., Hadidaꝉ, S., Grootenhuis, P. D. J., Burton, B., Cao, D., Neuberger, T., Turnbull, A., Singh, A. K., Joubran, J., Hazlewood, A., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0904709106 · Cited by 1,225
Self-citation
Guidelines for Diagnosis of Cystic Fibrosis in Newborns through Older Adults: Cystic Fibrosis Foundation Consensus Report
Farrell, P. M., Rosenstein, B. J., White, T. B., Accurso, F. J., Castellani, C., Cutting, G. R., Durie, P. R., LeGrys, V. A., Massie, J., Parad, R. B., et al. (2008) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2008.05.005 · Cited by 1,093
Cystic fibrosis: A worldwide analysis ofCFTR mutations?correlation with incidence data and application to screening
Bobadilla, J. L., Macek, M., Fine, J. P., & Farrell, P. M. (2002) · Human Mutation · doi:10.1002/humu.10041 · Cited by 1,032
Effect of VX-770 in Persons with Cystic Fibrosis and the G551D- CFTR Mutation
Accurso, F. J., Rowe, S. M., Clancy, J. P., Boyle, M., Dunitz, J., Durie, P. R., Sagel, S. D., Hornick, D. B., Konstan, M. W., Donaldson, S. H., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0909825 · Cited by 803
Self-citation
Altered chloride ion channel kinetics associated with the ΔF508 cystic fibrosis mutation
Dalemans, W., Barbry, P., Champigny, G., Jallat, S., Jallat, S., Dott, K., Dreyer, D., Crystal, R. G., Pavirani, A., Lecocq, J.-P., et al. (1991) · Nature · doi:10.1038/354526a0 · Cited by 707
Consensus on the use and interpretation of cystic fibrosis mutation analysis in clinical practice
Castellani, C., Cuppens, H., Maçek, M., Cassiman, J. J., Kerem, E., Durie, P. R., Tullis, E. D., Assael, B. M., Bombieri, C., Brown, A., et al. (2008) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2008.03.009 · Cited by 624
Small-molecule correctors of defective F508-CFTR cellular processing identified by high-throughput screening
Pedemonte, N. (2005) · Journal of Clinical Investigation · doi:10.1172/jci24898 · Cited by 551

Show all 44 references

Research works printed but not linked: 1

; Cystic Fibrosis Foundation US Cystic Fibrosis Patient Registry (Cystic Fibrosis Foundation, Bethesda, 2002).

Sorted by citations

Items 101–200 of 1,000

CFTR: A New Horizon in the Pathomechanism and Treatment of Pancreatitis
Hegyi, P. J., Wilschanski, M. A., Muallem, S., Lukács, G. L., Sahin‐Tóth, M., Uç, A., Gray, M. A., Rakonczay, Z., & Maléth, J. (2016) · Reviews of physiology, biochemistry and pharmacology · doi:10.1007/112_2015_5002 · Cited by 110
Orkambi® and amplifier co‐therapy improves function from a rare CFTR mutation in gene‐edited cells and patient tissue
Molinski, S. V., Ahmadi, S., Ip, W., Ouyang, H., Villella, A., Miller, J. P., Lee, P., Kulleperuma, K., Du, K., Paola, M. D., et al. (2017) · EMBO Molecular Medicine · doi:10.15252/emmm.201607137 · Cited by 104
Residual function of cystic fibrosis mutants predicts response to small molecule CFTR modulators
Han, S. T., Rab, A., Pellicore, M. J., Davis-Marcisak, E. F., McCague, A. F., Evans, T. A., Joynt, A. T., Lu, Z., Cai, Z., Raraigh, K. S., et al. (2018) · JCI Insight · doi:10.1172/jci.insight.121159 · Cited by 98
Pharmacological chaperoning: A primer on mechanism and pharmacology
Leidenheimer, N. J., & Ryder, K. G. (2014) · Pharmacological Research · doi:10.1016/j.phrs.2014.01.005 · Cited by 107
VX-809 and Related Corrector Compounds Exhibit Secondary Activity Stabilizing Active F508del-CFTR after Its Partial Rescue to the Cell Surface
Eckford, P. D. W., Ramjeesingh, M., Molinski, S. V., Pasyk, S., Dekkers, J. F., Li, C., Ahmadi, S., Ip, W., Chung, T., Du, K., et al. (2014) · Chemistry & Biology · doi:10.1016/j.chembiol.2014.02.021 · Cited by 100
Biosynthesis and trafficking of the bile salt export pump, BSEP: Therapeutic implications of BSEP mutations
Soroka, C. J., & Boyer, J. L. (2013) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2013.05.001 · Cited by 99
A Systematic Review of the Clinical Efficacy and Safety of CFTR Modulators in Cystic Fibrosis
Habib, A.-R. R., Kajbafzadeh, M., Desai, S., Yang, C. L., Skolnik, K., & Quon, B. S. (2019) · Scientific Reports · doi:10.1038/s41598-019-43652-2 · Cited by 98
Cystic Fibrosis Modulator Therapies
Jia, S., & Taylor‐Cousar, J. L. (2022) · Annual Review of Medicine · doi:10.1146/annurev-med-042921-021447 · Cited by 105
Targeting autophagy as a novel strategy for facilitating the therapeutic action of potentiators on ΔF508 cystic fibrosis transmembrane conductance regulator
Luciani, A., Villella, V. R., Esposito, S., Gavina, M., Russo, I., Silano, M., Guido, S., Pettoello‐Mantovani, M., Carnuccio, R., Scholte, B. J., et al. (2012) · Autophagy · doi:10.4161/auto.21483 · Cited by 101
In vitro modulator responsiveness of 655 CFTR variants found in people with cystic fibrosis
Bihler, H. J., Sivachenko, A., Millen, L., Bhatt, P., Thakerar, A., Chin, J., Bailey, V., Musisi, I., LaPan, A., Allaire, N., et al. (2024) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2024.02.006 · Cited by 106
Cryo-EM as a powerful tool for drug discovery
Drie, J. H. V., & Tong, L. (2020) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2020.127524 · Cited by 94
Novel opportunities for CFTR-targeting drug development using organoids
Dekkers, J. F., van der Ent, C. K., & Beekman, J. M. (2013) · Rare Diseases · doi:10.4161/rdis.27112 · Cited by 93
Lumacaftor/Ivacaftor Treatment of Patients with Cystic Fibrosis Heterozygous for F508del-CFTR
Rowe, S. M., McColley, S. A., Rietschel, E., Li, X., Bell, S. C., Konstan, M. W., Marigowda, G., Waltz, D., & Boyle, M. P. (2017) · Annals of the American Thoracic Society · doi:10.1513/annalsats.201609-689oc · Cited by 92
Identification of the amino acids inserted during suppression of CFTR nonsense mutations and determination of their functional consequences
Xue, X., Mutyam, V., Thakerar, A., Mobley, J. A., Bridges, R. J., Rowe, S. M., Keeling, K. M., & Bedwell, D. M. (2017) · Human Molecular Genetics · doi:10.1093/hmg/ddx196 · Cited by 99
Human Primary Epithelial Cell Models: Promising Tools in the Era of Cystic Fibrosis Personalized Medicine
Awatade, N. T., Wong, S. L., Hewson, C. K., Fawcett, L. K., Kicic, A., Jaffe, A., & Waters, S. A. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.01429 · Cited by 92
Novel pharmacological strategies to treat cystic fibrosis
Hanrahan, J. W., Sampson, H. M., & Thomas, D. Y. (2013) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2012.11.006 · Cited by 95
Modulation of the Maladaptive Stress Response to Manage Diseases of Protein Folding
Roth, D., Hutt, D. M., Tong, J., Bouchecareilh, M., Wang, N., Seeley, T., Dekkers, J. F., Beekman, J. M., Garza, D., Drew, L., et al. (2014) · PLoS Biology · doi:10.1371/journal.pbio.1001998 · Cited by 92
Combining Allosteric and Orthosteric Drugs to Overcome Drug Resistance
Ni, D., Li, Y., Qiu, Y., Pu, J., Lu, S., & Zhang, J. (2020) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2020.02.001 · Cited by 92
Direct Binding of the Corrector VX-809 to Human CFTR NBD1: Evidence of an Allosteric Coupling between the Binding Site and the NBD1:CL4 Interface
Hudson, R. P., Dawson, J. E., Chong, P. A., Yang, Z. W., Millen, L., Thomas, P., Brouillette, C. G., & Forman-Kay, J. D. (2017) · Molecular Pharmacology · doi:10.1124/mol.117.108373 · Cited by 93
Personalized Medicine in Cystic Fibrosis: Dawning of a New Era
Clancy, J. P., & Jain, M. (2012) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201204-0785pp · Cited by 89
From patient-specific induced pluripotent stem cells to clinical translation in long QT syndrome Type 2
Schwartz, P. J., Gnecchi, M., Dagradi, F., Castelletti, S., Parati, G., Spazzolini, C., Sala, L., & Crotti, L. (2019) · European Heart Journal · doi:10.1093/eurheartj/ehz023 · Cited by 89
Airway hydration and COPD
Ghosh, A., Boucher, R. C., & Tarran, R. (2015) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-015-1946-7 · Cited by 93
Altering Metabolic Profiles of Drugs by Precision Deuteration 2: Discovery of a Deuterated Analog of Ivacaftor with Differentiated Pharmacokinetics for Clinical Development
Harbeson, S. L., Morgan, A. J., Liu, J. F., Aslanian, A. M., Nguyen, S., Bridson, G. W., Brummel, C. L., Wu, L., Tung, R. D., Pilja, L., et al. (2017) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.117.241497 · Cited by 87
What is personalized medicine and what should it replace?
Whitcomb, D. C. (2012) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2012.100 · Cited by 91
Allele specific repair of splicing mutations in cystic fibrosis through AsCas12a genome editing
Maule, G., Casini, A., Montagna, C., Ramalho, A. S., De Boeck, K., Debyser, Z., Carlon, M. S., Petris, G., & Cereseto, A. (2019) · Nature Communications · doi:10.1038/s41467-019-11454-9 · Cited by 86
Discovery of novel potent ΔF508‐CFTR correctors that target the nucleotide binding domain
Odolczyk, N., Fritsch, J., Norez, C., Servel, N., da Cunha, M. F., Bitam, S., Kupniewska, A., Wiszniewski, L., Colas, J., Tarnowski, K., et al. (2013) · EMBO Molecular Medicine · doi:10.1002/emmm.201302699 · Cited by 88
Allosteric Modulation Balances Thermodynamic Stability and Restores Function of ΔF508 CFTR
Aleksandrov, A. A., Kota, P. B., Cui, L., Jensen, T., Alekseev, A. E., Reyes, S., He, L., Gentzsch, M., Aleksandrov, L. A., Dokholyan, N. V., et al. (2012) · Journal of Molecular Biology · doi:10.1016/j.jmb.2012.03.001 · Cited by 86
TGF-Beta Downregulation of Distinct Chloride Channels in Cystic Fibrosis-Affected Epithelia
Sun, H., Harris, W. T., Kortyka, S., Kotha, K. S., Ostmann, A. J., Rezayat, A., Sridharan, A., Sanders, Y. Y., Naren, A. P., & Clancy, J. P. (2014) · PLoS ONE · doi:10.1371/journal.pone.0106842 · Cited by 86
Rescuing Mutant CFTR: A Multi-task Approach to a Better Outcome in Treating Cystic Fibrosis
Amaral, M. D., & Farinha, C. M. (2013) · Current Pharmaceutical Design · doi:10.2174/13816128113199990318 · Cited by 88
Discovery of Clinically Approved Agents That Promote Suppression of Cystic Fibrosis Transmembrane Conductance Regulator Nonsense Mutations
Mutyam, V., Du, M., Xue, X., Keeling, K. M., White, E. L., Bostwick, J. R., Rasmussen, L. A., Liu, B., Mazur, M., Hong, J. S., et al. (2016) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201601-0154oc · Cited by 85
Chaperone-Independent Peripheral Quality Control of CFTR by RFFL E3 Ligase
Okiyoneda, T., Veit, G., Sakai, R., Aki, M., Fujihara, T., Higashi, M., Susuki-Miyata, S., Miyata, M., Fukuda, N., Yoshida, A., et al. (2018) · Developmental Cell · doi:10.1016/j.devcel.2018.02.001 · Cited by 83
Cystic Fibrosis Therapeutics
Hoffman, L. R., & Ramsey, B. W. (2013) · CHEST Journal · doi:10.1378/chest.12-1639 · Cited by 82
Transcription factors and miRNAs that regulate fetal to adultCFTRexpression change are new targets for cystic fibrosis
Viart, V., Bergougnoux, A., Bonini, J., Varilh, J., Chiron, R., Tabary, O., Molinari, N., Claustres, M., & Taulan‐Cadars, M. (2014) · European Respiratory Journal · doi:10.1183/09031936.00113214 · Cited by 86
Using Genome Sequence to Enable the Design of Medicines and Chemical Probes
Angelbello, A. J., Chen, J. L., Childs‐Disney, J. L., Zhang, P., Wang, Z.-F., & Disney, M. D. (2018) · Chemical Reviews · doi:10.1021/acs.chemrev.7b00504 · Cited by 81
TMEM16A in Cystic Fibrosis: Activating or Inhibiting?
Kunzelmann, K., Ousingsawat, J., Cabrita, I., Doušová, T., Bähr, A., Janda, M., Schreiber, R., & Benedetto, R. D. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.00003 · Cited by 81
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for Ivacaftor Therapy in the Context of CFTR Genotype
Clancy, J. P., Johnson, S. G., Yee, S. W., McDonagh, E. M., Caudle, K. E., Klein, T. E., Cannavo, M., & Giacomini, K. M. (2014) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2014.54 · Cited by 78
Tgf-β1 Inhibits Cftr Biogenesis and Prevents Functional Rescue of ΔF508-Cftr in Primary Differentiated Human Bronchial Epithelial Cells
Snodgrass, S. M., Cihil, K. M., Cornuet, P. K., Myerburg, M. M., & Swiatecka‐Urban, A. (2013) · PLoS ONE · doi:10.1371/journal.pone.0063167 · Cited by 79
Phenotypic profiling of CFTR modulators in patient-derived respiratory epithelia
Ahmadi, S., Bozóky, Z., Paola, M. D., Xia, S., Li, C., Wong, A. P., Wellhauser, L., Molinski, S. V., Ip, W., Ouyang, H., et al. (2017) · npj Genomic Medicine · doi:10.1038/s41525-017-0015-6 · Cited by 81
Use of a High-Throughput Phenotypic Screening Strategy to Identify Amplifiers, a Novel Pharmacological Class of Small Molecules That Exhibit Functional Synergy with Potentiators and Correctors
Giuliano, K. A., Wachi, S., Drew, L., Dukovski, D., Green, O., Bastos, C., Cullen, M. D., Hauck, S. I., Tait, B. D., Muñoz, B., et al. (2017) · SLAS DISCOVERY · doi:10.1177/2472555217729790 · Cited by 81
Ionocytes and CFTR Chloride Channel Expression in Normal and Cystic Fibrosis Nasal and Bronchial Epithelial Cells
Scudieri, P., Musante, I., Venturini, A., Guidone, D., Genovese, M., Cresta, F., Caci, E., Palleschi, A., Poeta, M., Santamaria, F., et al. (2020) · Cells · doi:10.3390/cells9092090 · Cited by 86
The epithelial sodium channel (ENaC) as a therapeutic target for cystic fibrosis lung disease
Moore, P. J., & Tarran, R. (2018) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2018.1501361 · Cited by 79
The cystic fibrosis transmembrane conductance regulator (CFTR) and its stability
Meng, X., Clews, J., Kargas, V. E., Wang, X., & Ford, R. C. (2016) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-016-2386-8 · Cited by 87
The CFTR trafficking mutation F508del inhibits the constitutive activity of SLC26A9
Bertrand, C. A., Mitra, S., Mishra, S., Wang, X., Zhao, Y., Pilewski, J. M., Madden, D. R., & Frizzell, R. A. (2017) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00178.2016 · Cited by 77
Self-citation
Discovery of 4-[(2 R ,4 R )-4-({[1-(2,2-Difluoro-1,3-benzodioxol-5-yl)cyclopropyl]carbonyl}amino)-7-(difluoromethoxy)-3,4-dihydro-2 H -chromen-2-yl]benzoic Acid (ABBV/GLPG-2222), a Potent Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Corrector for the Treatment of Cystic Fibrosis
Wang, X., Liu, B., Searle, X. B., Yeung, C. M., Bogdan, A. R., Greszler, S. N., Singh, A. K., Fan, Y., Swensen, A. M., Vortherms, T. A., et al. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b01339 · Cited by 78
Identifying the molecular target sites for CFTR potentiators GLPG1837 and VX-770
Yeh, H., Qiu, L., Sohma, Y., Conrath, K., Zou, X., & Hwang, T. (2019) · The Journal of General Physiology · doi:10.1085/jgp.201912360 · Cited by 75
Pseudomonas aeruginosa Reduces VX-809 Stimulated F508del-CFTR Chloride Secretion by Airway Epithelial Cells
Stanton, B. A., Coutermarsh, B., Barnaby, R., & Hogan, D. A. (2015) · PLoS ONE · doi:10.1371/journal.pone.0127742 · Cited by 77
Intracellular Delivery of Peptidyl Ligands by Reversible Cyclization: Discovery of a PDZ Domain Inhibitor that Rescues CFTR Activity
Qian, Z., Xu, X., Amacher, J. F., Madden, D. R., Cormet‐Boyaka, E., & Pei, D. (2015) · Angewandte Chemie International Edition · doi:10.1002/anie.201411594 · Cited by 76
Antibiotic–non-antibiotic combinations for combating extremely drug-resistant Gram-negative ‘superbugs’
Schneider‐Futschik, E. K., Reyes‐Ortega, F., Velkov, T., & Li, J. (2017) · Essays in Biochemistry · doi:10.1042/ebc20160058 · Cited by 76
Safety and efficacy of vanzacaftor–tezacaftor–deutivacaftor in adults with cystic fibrosis: randomised, double-blind, controlled, phase 2 trials
Uluer, A., MacGregor, G., Azevedo, P., Indihar, V., Keating, C. L., Mall, M. A., McKone, E. F., Ramsey, B. W., Rowe, S. M., Rubenstein, R. C., et al. (2023) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(22)00504-5 · Cited by 77
Role of TRPML and Two-Pore Channels in Endolysosomal Cation Homeostasis
Grimm, C. M., Hassan, S., Wahl‐Schott, C., & Biel, M. (2012) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.112.192880 · Cited by 76
Update on alpha-1 antitrypsin deficiency: New therapies
Lomas, D. A., Hurst, J. R., & Gooptu, B. (2016) · Journal of Hepatology · doi:10.1016/j.jhep.2016.03.010 · Cited by 77
Measurements of Functional Responses in Human Primary Lung Cells as a Basis for Personalized Therapy for Cystic Fibrosis
Awatade, N. T., Uliyakina, I., Farinha, C. M., Clarke, L. A., Mendes, K., Solé, A., Pastor, J., Ramos, M. M. P., & Amaral, M. D. (2014) · EBioMedicine · doi:10.1016/j.ebiom.2014.12.005 · Cited by 77
State of progress in treating cystic fibrosis respiratory disease
Flume, P. A., & VanDevanter, D. R. (2012) · BMC Medicine · doi:10.1186/1741-7015-10-88 · Cited by 81
Cystic fibrosis foundation pulmonary guidelines. Use of cystic fibrosis transmembrane conductance regulator modulator therapy in patients with cystic fibrosis
Ren, C. L., Morgan, R. L., Oermann, C., Resnick, H. E., Brady, C., Campbell, A., DeNagel, R., Guill, M., Hoag, J., Lipton, A., et al. (2018) · Annals of the American Thoracic Society · doi:10.1513/annalsats.201707-539ot · Cited by 74
How early studies on secreted and membrane protein quality control gave rise to the ER associated degradation (ERAD) pathway: The early history of ERAD
Needham, P. G., & Brodsky, J. L. (2013) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2013.03.018 · Cited by 72
A Therapy for Most with Cystic Fibrosis
Bear, C. E. (2020) · Cell · doi:10.1016/j.cell.2019.12.032 · Cited by 72
Recent advances in phenotypic drug discovery
Swinney, D. C., & Lee, J. A. (2020) · F1000Research · doi:10.12688/f1000research.25813.1 · Cited by 74
Partial Rescue of F508del-CFTR Stability and Trafficking Defects by Double Corrector Treatment
Capurro, V., Tomati, V., Sondo, E., Renda, M., Borrelli, A., Pastorino, C., Guidone, D., Venturini, A., Giraudo, A., Bertozzi, S. M., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22105262 · Cited by 72
Efficient suppression of endogenous CFTR nonsense mutations using anticodon-engineered transfer RNAs
Ko, W., Porter, J. J., Sipple, M. T., Edwards, K. M., & Lueck, J. D. (2022) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2022.04.033 · Cited by 72
Lumacaftor (VX-809) restores the ability of CF macrophages to phagocytose and kill Pseudomonas aeruginosa
Barnaby, R., Koeppen, K., Nymon, A. B., Hampton, T. H., Berwin, B. L., Ashare, A., & Stanton, B. A. (2017) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00461.2017 · Cited by 73
Systems Biology Brings New Dimensions for Structure-Based Drug Design
Pei, J., Yin, N., Ma, X., & Lai, L. (2014) · Journal of the American Chemical Society · doi:10.1021/ja504810z · Cited by 74
Progress in cystic fibrosis and the CF Therapeutics Development Network
Rowe, S. M., Borowitz, D., Burns, J. L., Clancy, J. P., Donaldson, S. H., Retsch‐Bogart, G. Z., Sagel, S. D., & Ramsey, B. W. (2012) · Thorax · doi:10.1136/thoraxjnl-2012-202550 · Cited by 74
PROMISE: Working with the CF community to understand emerging clinical and research needs for those treated with highly effective CFTR modulator therapy
Nichols, D. P., Donaldson, S. H., Frederick, C. A., Freedman, S. D., Gelfond, D., Hoffman, L. R., Kelly, A. T., Narkewicz, M. R., Pittman, J. E., Ratjen, F. A., et al. (2021) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2021.02.003 · Cited by 73
CFTR Modulators for the Treatment of Cystic Fibrosis.
Pettit, R. S., & Fellner, C. (2014) · PubMed Central · Cited by 72
Cystic fibrosis: Toward personalized therapies
Ikpa, P. T., Bijvelds, M. J. C., & de Jonge, H. R. (2014) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2014.02.008 · Cited by 76
Potentiating SLC transporter activity: Emerging drug discovery opportunities
Rives, M., Javitch, J. A., & Wickenden, A. D. (2017) · Biochemical Pharmacology · doi:10.1016/j.bcp.2017.02.010 · Cited by 72
Air-Liquid interface cultures to model drug delivery through the mucociliary epithelial barrier
Lee, R. E., Reidel, B., Nelson, M. R., Macdonald, J. K., Kesimer, M., & Randell, S. H. (2023) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2023.114866 · Cited by 71
Lumacaftor/Ivacaftor: A Review in Cystic Fibrosis
Deeks, E. D. (2016) · Drugs · doi:10.1007/s40265-016-0611-2 · Cited by 71
The Enigmatic Gut in Cystic Fibrosis: Linking Inflammation, Dysbiosis, and the Increased Risk of Malignancy
Garg, M., & Ooi, C. Y. (2017) · Current Gastroenterology Reports · doi:10.1007/s11894-017-0546-0 · Cited by 70
Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants (most commonly F508del)
Southern, K. W., Murphy, J. P., Sinha, I. P., & Nevitt, S. J. (2020) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd010966.pub3 · Cited by 74
EPAC1 activation by cAMP stabilizes CFTR at the membrane by promoting its interaction with NHERF1
Lobo, M. J., Amaral, M. D., Zaccolo, M., & Farinha, C. M. (2016) · Journal of Cell Science · doi:10.1242/jcs.185629 · Cited by 70
Chaperones rescue the energetic landscape of mutant CFTR at single molecule and in cell
Bagdány, M., Veit, G., Fukuda, R., Avramescu, R. G., Okiyoneda, T., Baaklini, I., Singh, J., Sovak, G., Xu, H., Apaja, P. M., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-00444-4 · Cited by 71
Correcting CFTR folding defects by small-molecule correctors to cure cystic fibrosis
Mijnders, M., Kleizen, B., & Braakman, I. (2017) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2017.09.014 · Cited by 69
Malfolded Protein Structure and Proteostasis in Lung Diseases
Balch, W. E., Sznajder, J. I., Budinger, S., Finley, D. J., Laposky, A. D., Cuervo, A. M., Benjamin, I. J., Barreiro, E., Morimoto, R. I., Postow, L., et al. (2013) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201306-1164ws · Cited by 70
Breakthrough therapies: Cystic fibrosis (CF) potentiators and correctors
Solomon, G. M., Marshall, S. G., Ramsey, B. W., & Rowe, S. M. (2015) · Pediatric Pulmonology · doi:10.1002/ppul.23240 · Cited by 79
Molecular pathogenesis of Spondylocheirodysplastic Ehlers‐Danlos syndrome caused by mutant ZIP13 proteins
Bin, B., Hojyo, S., Hosaka, T., Bhin, J., Kano, H., Miyai, T., Ikeda, M., Kimura‐Someya, T., Shirouzu, M., Cho, E., et al. (2014) · EMBO Molecular Medicine · doi:10.15252/emmm.201303809 · Cited by 68
Low free drug concentration prevents inhibition of F508del CFTR functional expression by the potentiator VX‐770 (ivacaftor)
Matthes, E., Goepp, J., Carlile, G. W., Luo, Y., Dejgaard, K., Billet, A., Robert, R., Thomas, D. Y., & Hanrahan, J. W. (2015) · British Journal of Pharmacology · doi:10.1111/bph.13365 · Cited by 68
Modulators of CFTR. Updates on clinical development and future directions
Bardin, E., Pastor, A., Semeraro, M., Golec, A., Hayes, K., Chevalier, B., Berhal, F., Prestat, G., Hinzpeter, A., Gravier‐Pelletier, C., et al. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113195 · Cited by 72
Emerging novel concept of chaperone therapies for protein misfolding diseases
Suzuki, Y. (2014) · Proceedings of the Japan Academy Series B · doi:10.2183/pjab.90.145 · Cited by 68
Synergy-Based Small-Molecule Screen Using a Human Lung Epithelial Cell Line Yields ΔF508-CFTR Correctors That Augment VX-809 Maximal Efficacy
Phuan, P., Veit, G., Tan, J. A., Roldán, A., Finkbeiner, W. E., Lukács, G. L., & Verkman, A. S. (2014) · Molecular Pharmacology · doi:10.1124/mol.114.092478 · Cited by 68
Growth and Nutrition in Cystic Fibrosis
Brownell, J. N., Bashaw, H., & Stallings, V. A. (2019) · Seminars in Respiratory and Critical Care Medicine · doi:10.1055/s-0039-1696726 · Cited by 72
MicroRNA-145 Antagonism Reverses TGF-β Inhibition of F508del CFTR Correction in Airway Epithelia
Kabir, F. M. L., Ambalavanan, N., Liu, G., Li, P., Solomon, G. M., Lal, C. V., Mazur, M., Halloran, B., Szul, T., Gerthoffer, W. T., et al. (2017) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201704-0732oc · Cited by 68
Pervasive mislocalization of pathogenic coding variants underlying human disorders
Lacoste, J., Haghighi, M., Haider, S., Reno, C., Lin, Z., Segal, D., Qian, W. W., Xiong, X., Teelucksingh, T., Miglietta, E. A., et al. (2024) · Cell · doi:10.1016/j.cell.2024.09.003 · Cited by 73
Lumacaftor and ivacaftor in the management of patients with cystic fibrosis: current evidence and future prospects
Kuk, K. N., & Taylor‐Cousar, J. L. (2015) · Therapeutic Advances in Respiratory Disease · doi:10.1177/1753465815601934 · Cited by 67
Combination therapy with cystic fibrosis transmembrane conductance regulator modulators augment the airway functional microanatomy
Birket, S. E., Chu, K. K., Houser, G. H., Liu, L., Fernandez, C. M., Solomon, G. M., Lin, V. Y., Shastry, S., Mazur, M., Sloane, P. A., et al. (2016) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00395.2015 · Cited by 66
A common mechanism for CFTR potentiators
Yeh, H., Sohma, Y., Conrath, K., & Hwang, T. (2017) · The Journal of General Physiology · doi:10.1085/jgp.201711886 · Cited by 66
Targeted deubiquitination rescues distinct trafficking-deficient ion channelopathies
Kanner, S. A., Shuja, Z., Choudhury, P., Jain, A., & Colecraft, H. M. (2020) · Nature Methods · doi:10.1038/s41592-020-00992-6 · Cited by 63
Restoration of NBD1 Thermal Stability Is Necessary and Sufficient to Correct ∆F508 CFTR Folding and Assembly
He, L., Aleksandrov, A. A., An, J., Cui, L., Yang, Z. W., Brouillette, C. G., & Riordan, J. R. (2014) · Journal of Molecular Biology · doi:10.1016/j.jmb.2014.07.026 · Cited by 65
Combination potentiator (‘co-potentiator’) therapy for CF caused by CFTR mutants, including N1303K, that are poorly responsive to single potentiators
Phuan, P., Son, J., Tan, J., Li, C. J., Musante, I., Zlock, L. T., Nielson, D. W., Finkbeiner, W. E., Kurth, M. J., Galietta, L. J. V., et al. (2018) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2018.05.010 · Cited by 65
CFTR Modulators: Impact on Fertility, Pregnancy, and Lactation in Women with Cystic Fibrosis
Taylor‐Cousar, J. L. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9092706 · Cited by 101
Long-term culture and cloning of primary human bronchial basal cells that maintain multipotent differentiation capacity and CFTR channel function
Peters‐Hall, J. R., Coquelin, M. L., Torres, M. J., LaRanger, R., Alabi, B. R., Sho, S., Calva-Moreno, J. F., Thomas, P., & Shay, J. W. (2018) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00355.2017 · Cited by 63
Discovery of CFTR modulators for the treatment of cystic fibrosis
Lopes‐Pacheco, M., Pedemonte, N., & Veit, G. (2021) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2021.1912732 · Cited by 65
Targeted therapies to improve CFTR function in cystic fibrosis
Brodlie, M., Haq, I., Roberts, K., & Elborn, J. S. (2015) · Genome Medicine · doi:10.1186/s13073-015-0223-6 · Cited by 65
In vivo and in vitro ivacaftor response in cystic fibrosis patients with residual CFTR function: N‐of‐1 studies
McGarry, M. E., Illek, B., Ly, N. P., Zlock, L. T., Olshansky, S., Moreno, C., Finkbeiner, W. E., & Nielson, D. W. (2017) · Pediatric Pulmonology · doi:10.1002/ppul.23659 · Cited by 63
Protein misfolding diseases: Prospects of pharmacological treatment
Gámez, A., Yuste‐Checa, P., Brasil, S., Briso‐Montiano, A., Desviat, L. R., Ugarte, M., Pérez‐Cerdá, C., & Pérez, B. (2017) · Clinical Genetics · doi:10.1111/cge.13088 · Cited by 64
Capitalizing on the heterogeneous effects of CFTR nonsense and frameshift variants to inform therapeutic strategy for cystic fibrosis
Sharma, N., Evans, T. A., Pellicore, M. J., Davis-Marcisak, E. F., Aksit, M. A., McCague, A. F., Joynt, A. T., Lu, Z., Han, S. T., Anzmann, A. F., et al. (2018) · PLoS Genetics · doi:10.1371/journal.pgen.1007723 · Cited by 64
The Impact of Highly Effective Modulator Therapy on Cystic Fibrosis Microbiology and Inflammation
Caverly, L. J., Riquelme, S. A., & Hisert, K. B. (2022) · Clinics in Chest Medicine · doi:10.1016/j.ccm.2022.06.007 · Cited by 64
HGF Stimulation of Rac1 Signaling Enhances Pharmacological Correction of the Most Prevalent Cystic Fibrosis Mutant F508del-CFTR
Moniz, S., Sousa, M., Moraes, B. J., Mendes, A. I., Palma, M., Barreto, C., Fragata, J., Amaral, M. D., & Matos, P. (2012) · ACS Chemical Biology · doi:10.1021/cb300484r · Cited by 64
The endoplasmic reticulum: A hub of protein quality control in health and disease
Vincenz‐Donnelly, L., & Hipp, M. S. (2017) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2017.03.031 · Cited by 64
Combined effects of VX-770 and VX-809 on several functional abnormalities of F508del-CFTR channels
Kopeikin, Z., Yuksek, Z., Yang, H. Y., & Bompadre, S. G. (2014) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2014.04.003 · Cited by 63

Authors: Van Goor, F., Hadida, S., Grootenhuis, P. D. J., Burton, B., Stack, J. H., Straley, K. S., Decker, C. J., Miller, M., McCartney, J., Olson, E. R., Wine, J. J., Frizzell, R. A., Ashlock, M., & Negulescu, P. A.
Affiliations: Vertex Pharmaceuticals, San Diego, CA 92121;
Vertex Pharmaceuticals (United States) (US)
Stanford University (US)
Department of Cell Biology and Physiology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15261; and
Cystic Fibrosis Foundation (US)
Corresponding author: Negulescu, Paul A.
ORCID: Miller, Mark
Olson, Eric R.
Wine, Jeffrey J.
Venue: Proceedings of the National Academy of Sciences
Publisher: National Academy of Sciences
Published: 2011-10-05
Volume: 108
Issue: 46
Pages: 18843-18848
ISSN: 0027-8424 (ISSN-L)
1091-6490
DOI: 10.1073/pnas.1105787108
PMC: PMC3219147
OpenAlex: W2071407356
Cited by: 1,088
References: 44
Citations by year: 2026: 24 · 2025: 48 · 2024: 48 · 2023: 57 · 2022: 64 · 2021: 83 · 2020: 98 · 2019: 95 · 2018: 101 · 2017: 103 · 2016: 77 · 2015: 85 · 2014: 84 · 2013: 61 · 2012: 58
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Locations: Proceedings of the National Academy of Sciences (publishedVersion)
PubMed Central (publishedVersion)
PubMed (publishedVersion)
Funders: Cystic Fibrosis Foundation Therapeutics
Topics: Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Cystic Fibrosis Research Advances
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Ion Transport and Channel Regulation
Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Inhalation and Respiratory Drug Delivery
Keywords: cystic fibrosis, F508del-CFTR, CFTR correctors, lumacaftor, endoplasmic reticulum retention, chloride secretion, bronchial epithelial cells, CFTR mutations
MeSH terms: Aminopyridines, Bronchi, Cell Line, Cells, Cultured, Chemistry, Pharmaceutical, Chlorides, Cystic Fibrosis, Drug Evaluation, Preclinical, Epithelial Cells, Homozygote, Humans, Lung, Models, Genetic, Mutation, Drug Design, Cystic Fibrosis Transmembrane Conductance Regulator, Benzodioxoles, In Vitro Techniques

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Correction of the F508del-CFTR protein processing defect in vitro by the investigational drug VX-809

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks